Eribulin Mesylate + Avelumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Urothelial Cell Cancer
Conditions
Metastatic Urothelial Cell Cancer
Trial Timeline
Jun 12, 2018 → Oct 25, 2019
NCT ID
NCT03502681About Eribulin Mesylate + Avelumab
Eribulin Mesylate + Avelumab is a phase 1 stage product being developed by Eisai for Metastatic Urothelial Cell Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03502681. Target conditions include Metastatic Urothelial Cell Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03502681 | Phase 1 | Terminated |
Competing Products
20 competing products in Metastatic Urothelial Cell Cancer